{
}
UBS has reiterated a Neutral rating on Royalty Pharma (NASDAQ: RPRX) with a target price of USD 33, despite the stock's 24.5% year-to-date gain. The company faces potential risks from changes in tax legislation, particularly concerning its zero tax rate structure, but is expected to remain profitable with projected earnings growth.In its recent fourth-quarter results, Royalty Pharma reported an EPS of USD 0.3531 and sales of USD 594 million, both below expectations. However, it achieved portfolio revenues of USD 2.8 billion for 2024 and plans a USD 2 billion share buyback, while Citi maintains a Buy rating with a target of USD 40, citing stability in its tax structure.
UBS analyst Ashwani Verma has maintained a Neutral rating on Royalty Pharma (NASDAQ: RPRX) with a price target of $33.00. The reiteration reflects the analyst's assessment of the company's current market position.
Royalty Pharma recently announced an increase in its quarterly dividend to $0.22, with the ex-dividend date set for February 21st. The company, which specializes in acquiring biopharmaceutical royalties, reported a net margin of 37.94% and a return on equity of 24.40%, with a current market capitalization of $18.89 billion. Analysts maintain a consensus "Buy" rating for the stock, with a target price of $41.60.
Novo Nordisk has partnered with Ascendis Pharma to develop a long-acting GLP-1 drug and other metabolic treatments, potentially paying up to $285 million based on progress. Ascendis will receive additional fees for each drug developed, leveraging its delivery technology to reduce dosing frequency. The collaboration aims to enhance patient adherence to medications for obesity and diabetes, addressing high discontinuation rates in current treatments.
Royalty Pharma plc
Companies
| Symbol | RPRX |
| Name | Royalty Pharma plc |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | NY |
| City | New York |
| Zipcode | 10022 |
| Website | http://www.royaltypharma.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains neutral stance on royalty pharma with stable price target
15:14 27.03.2025
ubs maintains neutral rating and price target for royalty pharma
14:26 27.03.2025
royalty pharma announces dividend increase and strong quarterly earnings results
08:53 15.03.2025
novo nordisk partners with ascendis to develop long acting glp 1 drugs
Euro
United States Dollar
Ascendis Pharma A/S
Novo Nordisk A/S
Royalty Pharma plc
DNK
Brian Vandahl
Royalty Pharma
Show more
17:52 04.11.2024
Trending
Subcategory
Stock Market Updates
Corporate News
Industry Trends
Banking Regulations
Finance Mergers & Acquisitions
Global Financial Events
Retail and Consumer Goods
Central Bank Actions
GDP Growth & Recession Forecasts
CEO Changes
Global Trade Developments
Industry Mergers & Acquisitions
Financial Scams and Security
Market Analysis and Predictions
Inflation and Monetary Impact
Government Policies
Government Economic Policies
Supply Chain Management
Domestic Politics
Workplace Trends
Countries:
Companies:
The Goldman Sachs Group, Inc.
JPMorgan Chase & Co.
Tesla, Inc.
Apple Inc.
Bank of America Corporation
Barclays PLC
Wells Fargo & Company
Citigroup Inc.
Deutsche Bank Money Market PP
Morgan Stanley
Huawei Technologies CO. Ltd.
Lloyds Banking Group plc
Credit Suisse Strategic Income I
AXA SA
Safran SA
Banco Santander, S.A.
Novartis AG
NVIDIA Corporation
Swiss Re AG
Beazley plc
Currencies:
United States Dollar
Euro
Chinese Yuan
British Pound Sterling
Swiss Franc
Japanese Yen
Indian Rupee
Russian Ruble
Canadian Dollar
Australian Dollar
United Arab Emirates Dirham
Indonesian Rupiah
Saudi Riyal
South Korean Won
Danish Krone
Offshore Chinese Yuan
Hong Kong Dollar
Mexican Peso
Malaysian Ringgit
Vietnamese Đồng
People: